Concentration change of NE, 5-HT and their metabolites in brain tissue in schizophrenia developmental models rat repeatedly treated with MK-801

Abstract

Abstract: AIM: To explore the related neurobiochemistry pathomechanism by the comparison of concentration of norepinephrine (NE), 5-hydroxytryptamine (5-HT) and their metabolites in brain tissue in the schizophrenia (SZ) developmental model rats. METHODS: 24 neonatal male Spragur-Dawley (SD) rats were randomly assigned at the postnatal day 6 to 3 groups: a SZ developmental model group (subcutaneous injection with MK-801 at the postnatal day 7-10, 0.1 mg/kg bid), a chronic medication model group (intraperitoneal injection at the postnatal day 47-60, 0.2 mg/kg,qd) and a normal control group (injection with 0.9% normal saline during the corresponding periods). NE, Methoxyhydr-oxyphenylglycol (MHPG), 5-HT and 5-hydroxyindo-leacetic acid (5-HIAA) of the tissue homogenate from the medial prefrontal cortex (mPFC) and hippocampus were examined with Coularray Electrochemic detection for high performance liquid chromatogram (HPLC) technique. Meanwhile, the utilization rate of NE and 5-HT was calculated. RESULTS: The NE and 5-HT concentration in the mPFC were significantly increased in SZ chronic medication model group compared with in normal control and SZ developmental model group, respectively (P<0.01 or 0.05); the 5-HIAA concentration in the mPFC were significantly increased in both SZ chronic medication and SZ developmental model group compared with in normal control group, respectively (P<0.01 or 0.05); compared to normal control and SZ chronic medication model group respectively, the MHPG concentration and NE utilization rate were significantly increased (P<0.05), and the 5-HT and 5-HIAA concentration were significantly decrease in hippocampus in the SZ developmental model group, respectively (P<0.01 or 0.05). CONCLUSION: The activity of 5-HT systems in the mPFC and hippocampus and NE systems in the hippocampus were decreased in SZ developmental model group.

Key words: Schizophrenia, Development, MK-801, NE, 5-HT

CLC Number:

R965.2

TANG Ya-mei, ZHANG Xiang-hui, LIU Yong. Concentration change of NE, 5-HT and their metabolites in brain tissue in schizophrenia developmental models rat repeatedly treated with MK-801[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 721-726.

References

[1] Uslaner JM, Smith SM, Huszar SL, et al. Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants[J]. Psychopharmacology , 2009, 206(4): 641-651.
[2] Drago A, Crisafulli C, Sidoti A, et al. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes[J]. Prog Neurobiol, 2011, 94(4): 418-460.
[3] Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment[J]. Psychopharmacology, 2011,213(2/3): 289-305.
[4] 汪春运. 谷氨酸与精神药理[J]. 医药导报, 2009, 28(5): 622-624.
[5] Stefani MR, Moghaddam B. Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia[J]. Biol Psychiatry, 2005, 57(4): 433-436.
[6] Rujescu D, Bender A, Keck M, et al. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities [J]. Biol Psychiatry, 2006, 59(8): 721-729.
[7] Wedzony K, Fijal K, Mackowiak M, et al. Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia[J]. Neuroscience, 2008, 153(4): 1370-1379.
[8] 刘勇,唐亚梅, 蒲唯丹, 等. MK-801诱导的精神分裂症发育模型大鼠脑组织DA、DOPAC、Glu 和GABA浓度的变化[J]. 中南大学学报:医学版, 2011, 36(8): 712-719.
[9] 倪尉, 周和平, 项光亚, 等. 非典型抗精神病药物的研究进展[J]. 医药导报, 2010, 29(3): 342-346.
[10] Cai HL, Fang PF, Li HD, et al. Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment[J]. Psychiatry Res, 2011, 188 (2): 197-202.
[11] Cai HL, Fang PF, Li HD, et al. Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment[J]. Psychiatry Res, 2011, 188 (2): 197-202.
[12] Wang C, Anastasio N, Popov V, et al. Blockade of N-methyl-D-aspartate receptors by phencyclidine causes the loss of corticostriatal neurons[J]. Neuroscience, 2004, 125(2): 473-483.
[13] Basta-Kaim A, Fijaŀ K, Budziszewska B, et al. Prenatal lipopolysaccharide treatment enhances MK-801-induced psychotomimetic effects in rats[J]. Pharmacol Biochem Behav, 2011, 98(2): 241-249.
[14] Ohuoha DC, Hyde TM, Kleinman JE, et al. The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system[J]. Psychopharmacology, 1993, 112(1): S5-15.
[15] Soderstrom H, Blennow K, Manhem A, et al. CSF studies in violent offenders. I. 5-HIAA as a negative and HVA as a positive predictor of psychopathy[J]. J Neural Transm, 2001, 108(7): 869-878.
[16] Korpi ER, Goodman SI, Kleinman JE, et al. Relationship between tryptophan and serotonin concentrations in postmortem human brain[J]. Med Biol, 1987, 65(4): 217-220.
[17] Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study[J]. Biol Psychiatry, 1997, 42(7): 529-545.
[18] Erritzoe D, Rasmussen H, Kristiansen KT, et al. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients[J]. Neuropsychopharmacology, 2008, 33(10): 2435- 2441.
[19] Labonte B, Bambico FR, Gobbi G, et al. Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex[J]. Naunyn Schmiedebergs Arch Pharmacol, 2009, 380(5): 383-397.
[20] Su YA, Si TM, Zhou DF, et al. Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors[J]. Eur J Pharmacol, 2007,564(1/2/3): 123-130.
[21] Kusljic S, Brosda J, Norman TR, et al. Brain serotonin depletion by lesions of the median raphe nucleus enhances the psychotomimetic action of phencyclidine, but not dizocilpine (MK-801), in rats[J]. Brain Res, 2005, 1049(2): 217-226.
[22] Hashimoto K, Fujita Y, Iyo M, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors[J]. Neuro psychopharmacology, 2007, 32(3): 514-521.
[23] Scheepers FE, Gispen-de Wied CC, Westenberg HG, et al. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients[J]. Neuro psychopharmacology, 2001, 25(4): 468-475.
[24] Yuen EY, Li X, Wei J, et al. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses[J]. Mol Pharmacol, 2012, 81(2): 113-119.